Acadia Pharmaceuticals officer proposes $159K sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ACAD officer Mark Schneyer reported a proposed sale of 5,849 common shares, with an aggregate market value of $158,800.35 and an approximate sale date of August 5, 2026. He acquired 5,849 shares from ACAD through a stock option exercise, with cash listed as the payment method, on August 5, 2026. May 19, 2025 is reported as the plan-adoption or instruction date if relying on Rule 10b5-1. Piper Sandler & Co Inc is named as broker.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Stock Option Exercise financial
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.